Why Biotech Companies Underprice Themselves
Pricing in life sciences is part science, part psychology, and part politics. Most companies get it wrong in the same direction — and it's not always the direction you'd expect.
More coming soon →
I studied biochemistry at Western Michigan University, where I received the Merck Index Award for distinguished achievement in the field. After graduating, I spent four years at Weill Cornell Medicine in research — working at the intersection of clinical and translational science.
I joined Gencove as the second employee and have helped build the company from the ground up. Over seven years, I've built the entire finance and operations function from scratch — growing alongside the business as it scaled to $7.5M in revenue. My background spans research science and corporate operations, which gives me an unusual vantage point: I can read a P&L and a methods section with equal comfort.
Operations & Finance — low-pass sequencing platform for agriculture and human genomics.
Chapter Lead — community of operators in tech and life sciences.
Research experience in clinical and translational medicine at one of the world's leading academic medical centers.
Biochemistry — Merck Index Award recipient for distinguished achievement.
Occasional observations on biotech, operations, and how things work.
Pricing in life sciences is part science, part psychology, and part politics. Most companies get it wrong in the same direction — and it's not always the direction you'd expect.
More coming soon →What running operations at a genomics company taught me about the gap between scientific rigor and business discipline.
More coming soon →The translation from scientist to operator isn't obvious. Here's what changed when I switched sides.
More coming soon →More posts coming. Reach out if there's something you'd like me to write about.
How the operational layer of biotech — the part that rarely gets written about — is actually where most companies win or lose. Not the science, not the fundraising, but whether the systems hold up when things get complicated.
Whether you want to discuss biotech, operations, or just say hello — my inbox is open.